PART I . This description contains certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein. We assume no obligation to update any forward-looking statements contained herein. Overview We are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targ...
Q2 FY2026 — expected 2026-09-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001493152-26-010282 | EDGAR | 78K words |
| 2025-03-14 | 2024-12-31 | 0001493152-25-010389 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001493152-24-011979 | EDGAR | — |
| 2023-04-17 | 2022-12-31 | 0001493152-23-012617 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0001493152-22-007664 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001493152-21-005122 | EDGAR | — |
| 2020-03-04 | 2019-12-31 | 0001493152-20-003343 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001564590-19-010173 | EDGAR | — |
| 2018-02-16 | 2017-12-31 | 0001193125-18-048564 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001193125-17-058912 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001493152-25-021257 | EDGAR | 15K words |
| 2025-08-08 | 2025-06-30 | 0001641172-25-022766 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001641172-25-009464 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001493152-24-045067 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001493152-24-031000 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019655 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040060 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027838 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016708 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032121 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001493152-22-021757 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013349 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001493152-26-014128 | EDGAR | 1K words |
| 2026-03-11 | 0001493152-26-009682 | EDGAR | — |
| 2026-01-22 | 0001493152-26-003237 | EDGAR | — |
| 2026-01-20 | 0001493152-26-002759 | EDGAR | — |
| 2025-12-15 | 0001493152-25-027745 | EDGAR | — |
| 2025-11-12 | 0001493152-25-021749 | EDGAR | — |
| 2025-10-21 | 0001493152-25-018725 | EDGAR | — |
| 2025-09-02 | 0001493152-25-012562 | EDGAR | — |
| 2025-08-11 | 0001641172-25-022908 | EDGAR | — |
| 2025-07-02 | 0001641172-25-017575 | EDGAR | — |
443 total filings indexed. 411 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001174940 |
| Ticker | OGEN |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | FL |
| Website | https://www.oragenics.com |
| Listed | 2003-07-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OGEN (~200 tokens, structured JSON with cryptographic provenance)